

Resource Summary Report

Generated by SPARC SAWG on Sep 15, 2026

Emory University NIH Tetramer Core Facility

RRID:SCR_026557

Type: Tool

Proper Citation

Emory University NIH Tetramer Core Facility (RRID:SCR_026557)

Resource Information

URL: <https://tetramer.yerkes.emory.edu>

Proper Citation: Emory University NIH Tetramer Core Facility (RRID:SCR_026557)

Description: Core produces and distributes of MHC/peptide tetramers and related reagents. Production and distribution to the research community of major histocompatibility complex (MHC) tetramers and related reagents for detection of T cell responses to viruses, bacteria, parasites, tumors, auto-antigens, and other model antigens. Reagents are provided to qualified investigators at no cost, except for shipping and handling fees and in cases where investigator is asked to provide the TCF with peptide or other appropriate ligands.

Synonyms: , NIH Tetramer Facility, NIH Tetramer Core Facility

Resource Type: access service resource, core facility, service resource

Keywords: ABRF, produces and distributes of MHC/peptide tetramers and related reagents, MHC/peptide tetramers, histocompatibility complex (MHC) tetramers,

Availability: Open

Resource Name: Emory University NIH Tetramer Core Facility

Resource ID: SCR_026557

Alternate IDs: ABRF_3093

Alternate URLs: <https://coremarketplace.org/?FacilityID=3093&citation=1>

Record Creation Time: 20250311T060327+0000

Record Last Update: 20260912T200507+0000

Ratings and Alerts

No rating or validation information has been found for Emory University NIH Tetramer Core Facility.

No alerts have been found for Emory University NIH Tetramer Core Facility.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 91 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

McClellan BL, et al. (2026) Reprogramming the immune suppressive tumor microenvironment in glioma enhances the efficacy of immune-mediated gene therapy. Molecular therapy. Oncology, 34(2), 201215.

Botta D, et al. (2026) Intranasal Immunization with Live-Attenuated RSV-Vectored SARS-CoV-2 Vaccines Elicits Antigen-Specific Systemic and Mucosal Immunity and Protects Against Viral Challenge and Natural Infection. Vaccines, 14(5).

Sun Q, et al. (2026) Selective Immune Silencing by Targeted TGF- β Agonists. bioRxiv : the preprint server for biology.

Najar TA, et al. (2026) Microbiota-induced T cell plasticity enables immune-mediated tumour control. Nature, 651(8104), 201.

Botta D, et al. (2026) Intranasal immunization with live-attenuated RSV-vectored SARS-CoV-2 vaccines elicits antigen-specific systemic and mucosal immunity and protects against viral challenge and natural infection. bioRxiv : the preprint server for biology.

Nagai M, et al. (2026) Ketogenic diet synergistic reprogramming of both host and microbiome promotes tissue regeneration. bioRxiv : the preprint server for biology.

Richter FC, et al. (2026) Crosstalk between CD8⁺ T cells and systemic bile acid metabolism shapes antiviral immunity and immunopathology. JCI insight, 11(12).

Pircher H, et al. (2026) Increased Constitutive Interferon- γ Levels and Altered CD4 T Cell Homeostasis Induced by Expression of a Viral Glycoprotein. European journal of immunology, 56(4), e70188.

Wittling MC, et al. (2026) T-cell Priming by High-Avidity Neoantigens in Lymph Nodes Augments Adoptive Immunotherapy. Cancer immunology research, 14(3), 463.

Maroney KJ, et al. (2026) CD8⁺ T cells cross-restricted by HLA-B*57 and HLA-E*01 recognize HIV Gag with different functional profiles. JCI insight, 11(3).

Panagioti E, et al. (2026) MAPKAP Kinase 2 Orchestrates Memory T Cell Inflation in Cytomegalovirus Infection. *bioRxiv : the preprint server for biology*.

Shein SA, et al. (2026) Selective elimination of circulating effector CD8 T cells via LT α R blockade separates anti-CD137 efficacy from toxicity. *Science advances*, 12(17), eaea8737.

Sun Q, et al. (2026) Facile induction of immune tolerance by an interleukin-2-TGF β surrogate agonist. *Nature*, 653(8115), 888.

Yengkhom D, et al. (2026) Tuberculosis preventive therapy in postpartum women with HIV modifies M. tuberculosis-specific and nonspecific immune responses. *Frontiers in immunology*, 17, 1722621.

Polidoro RB, et al. (2026) Intestinal Barrier Loss Enables Microbiota-Mediated Purinergic Suppression During Malaria. *bioRxiv : the preprint server for biology*.

Das A, et al. (2026) A Novel Mouse Model to Identify Antigen-Specific Immune Responses in Pancreatic Cancer Cachexia. *Cancers*, 18(4).

Myers JA, et al. (2026) E-cadherin expression promotes tumor growth via KLRG1-dependent pathways. *Journal of immunology (Baltimore, Md. : 1950)*, 215(4).

Moseman JE, et al. (2026) Plasmid DNA vaccines encapsulated in lipid nanoparticles elicit STING-dependent type 1 interferon release. *Molecular therapy. Advances*, 34(1), 201698.

Weinstein KN, et al. (2026) Defects in CD8 $^{+}$ T cell suppression by Foxp3- α E2 expressing regulatory T cells. *bioRxiv : the preprint server for biology*.

Burn TN, et al. (2026) Antigen reactivity defines tissue-resident memory and exhausted T cells in tumors. *Nature immunology*, 27(1), 98.